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Diabetes is associated with loss of functional pancreatic
b-cells, and restoration of b-cells is a major goal for re-
generative therapies. Endogenous regeneration of b-cells
via b-cell replication has the potential to restore cellular
mass; however, pharmacological agents that promote re-
generation or expansion of endogenous b-cells have been
elusive. The regenerative capacity of b-cells declines rap-
idly with age, due to accumulation of p16INK4a, resulting
in limited capacity for adult endocrine pancreas regener-
ation. Here, we show that transforming growth factor-b
(TGF-b) signaling via Smad3 integrates with the trithorax
complex to activate and maintain Ink4a expression to pre-
vent b-cell replication. Importantly, inhibition of TGF-b sig-
naling can result in repression of the Ink4a/Arf locus,
resulting in increased b-cell replication in adult mice. Fur-
thermore, small molecule inhibitors of the TGF-b pathway
promote b-cell replication in human islets transplanted in-
to NOD-scid IL-2Rgnullmice. These data reveal a novel role
for TGF-b signaling in the regulation of the Ink4a/Arf locus
and highlight the potential of using small molecule in-
hibitors of TGF-b signaling to promote human b-cell
replication.
Replication of b-cells is the primary mechanism for main-
tenance and expansion of b-cell mass in response to
changing insulin demands (1–4), and failure of such adap-
tive expansion can result in diabetes (5,6). Induction of
p16INK4a expression, a product of the Ink4a/Arf locus, is
typical in adult tissues (7,8) and contributes to reduced
self-renewal across mammalian tissues, including b-cells
(9–11). This reflects in the reduced ability of the endo-
crine pancreas for adaptive expansion and regeneration
(12,13). The Ink4a/Arf locus has also been linked with
type 2 diabetes in genome-wide association studies (14).
Thus, manipulation of mechanisms that regulate the
Ink4a/Arf locus could serve a tool for promoting adult
b-cell replication.
Several studies, including ours, have shown that distinct
repressive complexes of polycomb group proteins regulate
b-cell replication during aging by epigenetically targeting
the Ink4a/Arf locus (15,16). Polycomb repressive complex 2
(PRC2) contains histone H3K27 methyltransferase Ezh2 and
marks the target chromatin with lysine 27 trimethylation of
histone H3 (H3K27me3). This directs the recruitment of
polycomb repressive complex 1 (PRC1; contains Bmi1
and ubiquitin ligase-Ring1B), leading to the ubiquitination
of lysine 119 in histone H2 (H2AK119) (11,17). Together,
these epigenetic modifications result in the repression
of the Ink4a/Arf locus in juvenile b-cells to maintain rep-
licative potential. The loss of polycomb complex binding
in adult b-cells results in the recruitment of histone
methyltransferase Mll1, which mediates trimethylation
of lysine 4 in histone H3 (H43K4me3), an activating his-
tone modification (15,16). In b-cells, Mll1 exists in a
complex with histone H3K27me3 demethylase JmjD3,
which removes the repressive H3K27me3 modifications
(18). Together, the recruitment of the Mll1-JmjD3 complex
leads to the induction of p16INK4a expression (15,16,18),
resulting in reduced b-cell replication. Our recent work
shows that a combination of polycomb replenishment
with loss of Mll1 complex binding can drive replication
in adult b-cells (18).
Although recent work has unraveled cellular signals,
such as platelet-derived growth factor that regulate the
repression of p16INK4a expression and b-cell self-renewal
in young adults (19), the signals that mediate the induction
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of Ink4a/Arf locus in late adult life are not known. Here, we
report that transforming growth factor-b (TGF-b) signaling
induces Ink4a expression leading to replicative decline in
b-cells through the recruitment of Smad3 as a part of the
Mll1 complex. Smad3 is a downstream effector of the
canonical TGF-b signaling and translocates to the nucleus
upon its phosphorylation as a consequence of ligand bind-
ing to the TGF-b receptor (20). We demonstrate that in-
hibition of TGF-b signaling using small molecules can
reduce the levels of p16INK4a in a conserved fashion across
cell types. Finally, we show that small molecule inhibitors
of TGF-b signaling can be used to induce b-cell replica-
tion by lowering the cellular levels of p16INK4a. Together,
these studies provide a therapeutically relevant example
of how cellular signals modulate b-cell replication via
targeting epigenetic pathways.
RESEARCH DESIGN AND METHODS
Animal Maintenance
For the experiments involving mouse islets and mouse in
vivo regeneration studies, the animals were maintained
by mating wild-type males and females on a C57BL/6J
background. Male NOD Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-
scid IL-2Rgnull [NSG]) (denoted NOD-scid-g or NSG) mice
(8–10 weeks old) were used for human islet transplant
experiments. All animal experiments were performed in
accordance with National Institutes of Health policies on
the use laboratory animals and approved by the Animal
Research Committee of the Office for the Protection of
Research Subjects at the University of California, Los
Angeles, and Joslin Diabetes Center Institutional Animal
Care and Use Committee protocols.
Animal Experiments
For experiments on the effect of TGF-b inhibitor on
mouse b-cell replication in vivo, wild-type C57BL/6J
mice (age 9 months) were divided into two groups (n = 9
per group) and injected intraperitoneally with a single
dose of TGF-b inhibitor SB431542 (5 mg/kg body weight
[BW]) or vehicle control (50% [v/v] DMSO), ensuring
that the volume injected was kept up to 100 mL. Previous
long-term studies have shown that the concentration of
DMSO used as vehicle in these studies has no adverse
effects on mouse health (21). Pancreata from these mice
were harvested and processed for histology and analyzed
for proliferation after 1 week (4). For human islet graft
experiments, male NSG mice (n = 4) were used for exper-
iments and grafted with human islets (1,000 islet equiv-
alents) under the kidney capsule as previously described
(22,23). One week after transplantation (when the islets
developed vascular anastomosis), mice were injected intra-
peritoneally with vehicle or TGF-b inhibitor (5 mg/kg/BW,
50% [v/v] DMSO) twice weekly for 3 weeks. Four weeks
after transplantation, mice were intraperitoneally injected
with BrdU (Sigma-Aldrich, St. Louis, MO) (100 mg/kg/BW)
for 3 days and killed 6 h after receiving the final BrdU
injection. Blood was collected before and 2 and 4 weeks
after islets were grafted for the measurement of human
insulin (Human Insulin ELISA Kit; Mercodia) and human
C-peptide (C-Peptide ELISA Kit; Mercodia). In vivo glucose-
stimulated insulin secretion (3 g/kg/BW, 20% dextrose)
was performed at 3 weeks post-transplantation after
overnight fasting. The graft-containing kidneys and
pancreata were embedded in paraffin and prepared for
histological analysis (24).
Cell Culture, Islet Isolation, and Culture-Inhibitor
Treatments
Mouse embryonic fibroblasts (MEFs) were maintained on
dishes coated with 0.2% porcine gelatin in DMEM-based
medium containing 10% FBS at 37°C in a 5% CO2 envi-
ronment. Mouse islets were isolated using the Liberase/
DNase enzyme mix (Roche Diagnostics) as previously de-
scribed (25). In brief, the pancreas was inflated with the
enzyme mix through the common bile duct and digested
at 37°C. Islets were enriched by gradient and handpicked.
Human islet samples from healthy adult organ donors
without diabetes who died of acute trauma or anoxia
were obtained from the Integrated Islet Distribution Pro-
gram, as previously described (4). From 100 to 200 islets
were cultured in a 35 mm 3 10 mm easy-grip tissue
culture dish (Falcon) in DMEM (CellGro) containing 10%
FBS, supplemented with 11 mmol/L D-glucose (mouse islets)
or 5 mmol/L D-glucose (human islets). For experiments in-
volving the effect of TGF-b on cellular aging and prolifera-
tion, early-passage MEFs (passage 2 [P2]) in culture were
supplemented with 5.0 ng/mL TGF-b (PeproTech) for 2
days (for proliferation assay) and for the indicated number
for days (for growth curve), with daily change of culture
medium. For experiments with TGF-b inhibitors, islets
from old mice (8–12 months old) and late-passage MEFs
(passage 9–12 [P9–12]) were cultured with one of the fol-
lowing TGF-b inhibitors, SB431542 (15 mmol/L; Sigma-
Aldrich), SB505124 (5 mmol/L; Sigma-Aldrich), or SD208
(10 mmol/L; Sigma-Aldrich), or control small molecule
phosphatidylinositide 3 kinase inhibitor LY294002
(10 mmol/L; Sigma-Aldrich) for 3 days for replication
analysis and the indicated number of days for cell growth
curves, with daily change of culture medium. For cell
growth measurements, the number of cells was measured
at indicated times and after indicated treatments by using
a hemocytometer and plotted as a function of time. Hu-
man islets from cadaveric donors were cultured for 4 days
with SB431542 (40 mmol/L; Sigma-Aldrich) or vehicle
control (DMSO) and then harvested for replication anal-
ysis. Western blots with the indicated antibodies were
performed, as previously described (25).
Immunofluorescence Staining and Morphometric
Analyses
A standard immunofluorescence staining protocol was
used to detect various protein markers in mouse pancre-
atic islet sections (4). Cultured islets were harvested, fixed
in 4% paraformaldehyde, embedded in histogel matrix,
and processed according to the above protocol. MEFs
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were fixed as monolayers in culture (on gelatin-coated
plastic ware) for 20–30 min at room-temperature with
the BD Cytofix/Cytoperm solution (BD Pharmingen) and
washed thoroughly three times with 13 BD Perm/Wash
buffer, followed by permeabilization at room temperature
in the same buffer. Primary antibodies were diluted in the
blocking solution (3% BSA in Tris-buffered saline with
Tween) at the following dilutions: guinea pig anti-insulin
(diluted 1:400; Dako), mouse anti-Ki67 (diluted 1:50; BD
Pharmingen), mouse anti-BrdU (diluted 1:2; GE Healthcare/
Amersham RPN-202); anti-phosphorylated histone H3
(diluted 1:200; Millipore pHH3), rabbit anti-Pdx1 (diluted
1:200; Millipore), and mouse anti-p16 (diluted 1:400; Santa
Cruz sc-1661). Donkey- and goat-derived secondary anti-
bodies conjugated to FITC or Cy3 were diluted 1:500
(Jackson ImmunoResearch Laboratories).
Slides were viewed using a Leica DM6000 microscope,
and images were acquired using Openlab software (Impro-
vision). The proliferation index was calculated using Ki67,
BrdU, or pHH3 staining as a measure of cell proliferation by
costaining the islet sections for Ki67 (or BrdU or pHH3) and
insulin or Pdx1 for b-cells and by costaining for Ki67
with the nuclear marker DAPI for MEFs. b-Cell area was
evaluated by point-counting morphometry on immuno-
fluorescence-stained pancreatic sections. Cell death was
detected by TUNEL assay (ApopTag S7100; Millipore).
At least 2,000–3,000 b-cell nuclei were counted per
animal.
Immunoprecipitation and Western Blotting
As previously published, 2.5 mg anti-Mll1 antibody (Milli-
pore 05-765) or control IgG was used for each immunopre-
cipitation on MEF lysates. Briefly, antibodies were bound
to Protein G Sepharose (Millipore) for 2–3 h and incubated
with MEF extracts prepared overnight at 4°C on a rotator.
The immunoprecipitates were analyzed by Western blotting
with antibodies against JmjD3 (Millipore; 07-1434), Smad3
antibody (Bethyl Laboratories; A300-109A), and control
Dnmt3a (Imgenex; IMG-268A). Samples for Western blot-
ting were lysed in cell dissociation buffer (Invitrogen)
supplemented with protease inhibitors cocktail (Calbiochem),
as described. The following primary antibodies were used:
mouse anti-p16 (Santa Cruz; sc-1661), mouse anti-Smad3
(BD Biosciences; 610842), rabbit anti-phosphorylated
(p)Smad3 (07-1389), and mouse anti–b-tubulin (Sigma-
Aldrich; T8328). Each Western blot is a representative
from three independent experiments using different sam-
ple preparations.
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation (ChIP) was performed as
previously reported (26), with minor modifications. The
islets (150–200 islets per group, made into single-cell sus-
pension) or MEFs (1 3 105 cells) were treated with 1%
paraformaldehyde at room temperature for 20 min to
crosslink the DNA with bound proteins. Formaldehyde
was quenched by adding glycine to a final concentration
of 125 mmol/L, followed by cell lysis in 100 mL lysis
buffer consisting of 50 mmol/L Tris HCl (pH 8.0),
10 mmol/L EDTA, 1% SDS, supplemented with 13 com-
plete proteinase inhibitors (Calbiochem), and sonicated to
yield DNA fragments with an average size of 500 bp
using Bioruptor (Diagenode). A total of 2.5 mg antibody
was bound to 20 mL Protein-A/G Dynabeads (Invitrogen),
depending on the antibody isotype, for 2 h at 4°C with
agitation. The following antibodies were used: anti–3me-
H3K27 (Millipore; 07-449), anti–H3K4 me3 (Cell Signal-
ing; 9751S), anti-JmjD3 (Millipore; 07-1534), anti-MLL1
(Millipore; 05-765), and anti-Smad3 (BD Biosciences;
610842), or normal mouse IgG as a control. One-fourth
fraction of the sonicated chromatin was incubated over-
night at 4°C with the antibody-bead complexes in total
volume of 200 mL in RIPA buffer containing 10 mmol/L
Tris HCl (pH 8.0), 140 mmol/L NaCl, 1 mmol/L EDTA,
1% Triton X-100, 0.1% SDS, and 0.1% Na-deoxycholate
supplemented with 13 complete proteinase inhibitors.
After washing four times with radioimmunoprecipitation
assay buffer and twice with Tris-EDTA buffer, chromatin
was eluted, followed by reverse crosslinking at 68°C for
4 h with vigorous agitation in the presence of Proteinase
K (Sigma-Aldrich). The DNA fragments were then purified
using phenol-chloroform extraction and ethanol precipi-
tation. The resulting DNA was quantified and served as a
template for the real-time PCR reactions, performed using
ABI7900HT (Applied Biosystems), with 13 Fast SYBR
Green Mix (Applied Biosystems). The DNA enrichment
after ChIP was estimated as percentage bound-to-input
ratio determined by real-time PCR. The primers used to
amplify the Ink4a/Arf locus have been described before
(11,16).
Statistical Methods
All data are expressed as mean 6 SE. Mean and SEM
values were calculated from at least triplicates of a represen-
tative experiment. The statistical significance of differences
was measured by unpaired Student t test for experiments
with two groups and a continuous outcome or by one-way
ANOVA for repeat measures. A P value of ,0.05 indicated
statistical significance.
RESULTS
TGF-b Signaling Induces the Expression of p16INK4a via
Recruitment of the Mll1 Complex
To understand the mechanisms that mediate the recruit-
ment of the Mll1 complex to the Ink4a/Arf locus during
replicative decline, we first used the MEFs model. P2
MEFs are characterized by low p16INK4a and high prolifera-
tion, whereas P9–12 MEFs accumulate p16INK4a, resulting in
reduced proliferation (11,18). Coimmunoprecipitation of
Mll1 complex components, followed by mass spectrometry,
suggested that the Mll1 complex interacted with the TGF-b
signaling pathway effectors (data not shown). Therefore, we
assessed the interaction between the Mll1 complex and
TGF-b pathway using anti-Mll1 antibody immunoprecipitate
from P9 MEFs. Western blotting using the Smad3 antibody
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revealed that Smad3 interacts with Mll1 (Fig. 1A and B).
Using ChIPs, we compared the binding of Smad3 to the
Ink4a/Arf locus in P2 and P9 MEFs. Smad3 was recruited
to the Ink4a/Arf locus in the P9 MEFs, suggesting a corre-
lation between Smad3 binding and induction of p16INK4a
(Fig. 1C). This was further confirmed by treatment of
P2 MEFs with TGF-b, which resulted in recruitment of
Smad3 to the Ink4a/Arf locus, along with Mll1 and JmjD3
(Fig. 1D and Supplementary Fig. 1A), resulting in in-
creased H3K4me3 (activating histone modification) and
reduced H3K27me3 (repressive modification) levels (Sup-
plementary Fig. 1B and C). This resulted in a significant
reduction in the proliferation of P2 MEFs treated with
TGF-b, due to the accumulation of p16INK4a (Fig. 1E–G
and Supplementary Fig. 1D), which was associated with
increased levels of pSmad3 (Supplementary Fig. 1E). Taken
together, these observations suggested a novel role for
TGF-b in the transcriptional regulation of Ink4a/Arf locus.
Inhibition of TGF-b Signaling Disrupts the Association
of Smad3 With the Ink4a/Arf Locus to Promote
Proliferation in P9 MEFs
To confirm if TGF-b signaling is associated with reduced
proliferative potential through induction of p16INK4a ex-
pression, we treated P9 MEFs with SB431542 (27), a well-
characterized inhibitor of TGF-b signaling that blocks
phosphorylation of Smad3 via the ALK5 receptor. Treat-
ment of P9 MEFs with SB431542 reduced the association
of Smad3 (Fig. 2A), Mll1, and JmjD3 to the Ink4a/Arf
locus (Fig. 2B), resulting in reduced H3K4me3 and in-
creased H3K27me3 levels (Supplementary Fig. 2A and
B). This led to reduced levels of p16INK4a and increased
Figure 1—A: Coimmunoprecipitation analysis examining the interaction of Mll1 complex with Smad3. Cell extracts from P9 MEFs were
used as input for immunoprecipitation (IP) with anti-Mll1 antibody (or control IgG) and analyzed by immunoblotting with Mll1, JmjD3, and
Smad3 antibodies. Bmi1 antibody was used as a negative control. Representative experiment from n = 3. B: Schematic representation of
the Ink4a/Arf locus, with blue regions marked 1–4 indicating the amplified regions in the ChIP studies. C: ChIP analysis comparing the
recruitment of Smad3 (using a Smad3 antibody) to the Ink4a/Arf locus, in P2 and P9 MEFs (n = 3). 1–4 indicate the amplified regions at the
Ink4a/Arf locus, and 5 indicates binding for the negative control corresponding to exon 2 in the Hox13C locus (43). D: ChIP analyses
comparing the recruitment of Smad3 and Mll1 to the Ink4a/Arf locus, in P2 MEFs treated with TGF-b or vehicle control (n = 3). 1–5 indicate
the amplified regions, with 5 being the negative control. Immunofluorescence (E ) and quantification (F ) for proliferation in P2 MEFs treated
with TGF-b or vehicle control (C), using immunostaining with Ki67 antibody (red). DAPI (blue) is a nuclear counterstain. Representative
experiment from n = 3. G: Western blotting for p16 and b-tubulin in cell extracts from P2 MEFs treated with TGF-b or vehicle control (C)
(n = 3). Error bars indicate 6 SEM. P values were determined by unpaired Student t test. *P < 0.05; **P < 0.01.
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proliferation of P9 MEFs treated with SB431542 (Fig. 2C–
E and Supplementary Fig. 2C). This suggested that indeed
the decline in proliferative potential due to p16INK4a ac-
cumulation in P9 MEFs is mediated by TGF-b signaling.
To test if the effect of TGF-b inhibitor on induction of
proliferation was reversible, we cultured P9 MEFs in the
presence of SB431542, followed by inhibitor withdrawal
after 4 days of treatment. Withdrawal of SB431542 resulted
in a decline in the proliferation compared with P9 MEFs
that were continuously maintained in the presence of inhib-
itor (Supplementary Fig. 2D), suggesting a transient effect of
TGF-b inhibitor on increasing proliferation.
TGF-b Inhibition Can Induce b-Cell Replication in Islets
From Adult Mice by Reducing p16INK4a Levels
On the basis of the observations in MEFs, we examined
the effect of TGF-b signaling on regulation of the Ink4a/Arf
locus in islets. ChIP analysis showed increased recruit-
ment of Smad3 to the Ink4a/Arf locus in islets from
9-month-old mice compared with islets from younger juvenile
mice (Fig. 3A). Treatment of pancreatic islets isolated from
9- to 12-month-old mice with SB431542 resulted in reduced
binding of Smad3, Mll1, and JmjD3 complex to the Ink4a/
Arf locus (Fig. 3B and Supplementary Fig. 3A), concomitant
with increased H3K27me3 and reduced H3K4me3 levels at
the Ink4a/Arf locus (Supplementary Fig. 3B and C). We then
cultured the islets from adult mice (aged 9–12 months) with
TGF-b inhibitor or vehicle control. The b-cells (marked by
Pdx1) from islets treated with SB431542 showed increased
replication (Fig. 3C and D) due to reduced levels of p16INK4a
in these islets (Fig. 3E). The specific effect of inhibition of
TGF-b signaling on b-cell replication was further confirmed
by treatment of islets from aged mice with two other known
TGF-b signaling inhibitors, namely SB505124 and SD208,
which showed a similar effect on increased replication,
whereas LY294002, a phosphatidylinositide 3 kinase in-
hibitor used as a control, did not result in any significant
increase in replication (Supplementary Fig. 3D and E).
Thus, treatment with small molecule inhibitors of TGF-b
signaling can promote b-cell replication in islets from adult
mice that typically exhibit resistance to induction of repli-
cation and regeneration (13).
Treatment of Mice With TGF-b Inhibitor Stimulates
b-Cell Replication
To establish whether treatment with TGF-b inhibitor can
stimulate b-cell regeneration in adult mice in vivo, we
injected 9-month-old mice intraperitoneally with one dose
of SB431542 or vehicle control (n = 9 per group). The pan-
creas was harvested after 1 week, and coimmunostaining of
Figure 2—A: ChIP analysis comparing the recruitment of Smad3 to the Ink4a/Arf locus, in P9 MEFs in the presence (MEFs+inh) or absence
of TGF-b inhibitor (n = 3). 1–5 indicate the amplified regions, with 5 being the negative control. B: ChIP analyses comparing the recruitment
of Mll1 and JmjD3 to the Ink4a/Arf locus, in P9 MEFs treated with TGF-b inhibitor (MEFs+inh) or vehicle control (n = 3). 1–5 indicate the
amplified regions, with 5 being the negative control. Immunofluorescence (C) and quantification (D) for proliferation in P9 MEFs treated
with TGF-b inhibitor (Inh) or vehicle control (C), using immunostaining with Ki67 antibody (red), counterstained with DAPI (blue) to mark
the nuclei (n = 3). E: Western blotting for p16 and b-tubulin in cell extracts from P9 MEFs treated with TGF-b inhibitor (Inh) or vehicle control
(C). Representative experiment from n = 3. Error bars indicate 6 SEM. P values were determined by unpaired Student t test. *P < 0.05;
**P < 0.01; ***P < 0.001.
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pancreatic sections for Ki67 and insulin showed increased
b-cell replication of SB431542 in treated mice compared
with control mice (Fig. 4A and B). The increase in b-cell
proliferation was accompanied by a reduction in p16INK4a
levels in islets (Fig. 4C). We previously showed that polycomb
regulation of p16INK4a-dependent changes that limits b-cell
replication is conserved in human islets (18). We then
examined whether b-cell replication can be induced in
human islets by inhibition of the TGF-b pathway. Treat-
ment of human islets (from donors aged 40–60) with
SB431542 resulted in increased b-cell replication com-
pared with vehicle control (Fig. 4D). The increased rep-
lication in the inhibitor-treated group correlated with
reduced binding of Mll1 and Smad3 at the Ink4a/Arf
locus (Supplementary Fig. 4A and B). Thus, inhibition
of TGF-b signaling improves b-cell replication in both
mice and humans.
TGF-b Inhibitor Stimulates b-Cell Replication in
Grafted Human Islets
To further evaluate the stimulatory effect of TGF-b in-
hibitor on human b-cell proliferation, we used a model in
which 1,000 human islet equivalents were transplanted
under the kidney capsule of male NSG mice (28). One
week after transplantation, mice receiving human islet
grafts were treated with the TGF-b inhibitor (5 mg/kg/BW,
50% [v/v] DMSO) or vehicle control (DMSO), and sham-
operated mice did not receive any treatment. Graft sur-
vival and functionality was examined by insulin secretory
responses to glucose, using an ultrasensitive human in-
sulin ELISA assay, in mice that received human islets
(Supplementary Fig. 5A). Detection of human insulin
and C-peptide levels in the circulation 2 and 4 weeks after
transplantation indicated the presence of viable human
islet grafts (Supplementary Fig. 5B and C). Immunohisto-
chemical analysis of human islet graft–bearing kidney sec-
tions showed a ;10-fold (P , 0.05) increase in BrdU
incorporation in the TGF-b inhibitor–treated group, indi-
cating a transition from G1 to S-phase of the cell cycle (Fig.
5A–G and Supplementary Fig. 5D). The enhanced mitosis
was confirmed by an approximately fourfold (P , 0.05)
increase in Ki67+ b-cells in the treated group (Fig. 5H and
Supplementary Fig. 5E), and an augmentation in pHH3+
b-cells suggesting progression into the G2/M phases (P =
0.07) (Fig. 5I). In untreated mice, the rate of human b-cell
replication was virtually undetectable, consistent with pre-
vious findings under similar conditions (22,23). Analysis of
p16INK4a expression in these graft samples by immunohis-
tochemistry showed reduced p16INK4a levels upon treat-
ment with TGF-b inhibitor, consistent with our earlier
observations in mice (Fig. 5J). Furthermore, examination
of endogenous mouse pancreas of both groups demon-
strated significantly lower b-cell apoptosis (P = 0.005) in
the TGF-b inhibitor–treated group compared with control
Figure 3—A: ChIP analysis comparing the recruitment of Smad3 to the Ink4a/Arf locus in islets from young (2.5 months) or old (9 months)
mice (n = 3). 1–5 indicate the amplified regions, with 5 being the negative control. B: ChIP analyses comparing the binding of Smad3 and
Mll1 in islets from old (9 months) mice, treated with TGF-b inhibitor SB431542 (inhibitor) or vehicle control (n = 3). 1–5 indicate the amplified
regions, with 5 being the negative control. Immunohistochemistry (C) and quantification (D) for proliferation of b-cells in islets from
9-month-old mice treated with TGF-b inhibitor or vehicle control, using immunostaining with Ki67 antibody (red) and b-cell marker Pdx1
(green). Arrowheads mark Ki67 Pdx1 double-positive cells. Counterstain DAPI (blue) marks the nuclei (n = 3). E: Western blotting for p16
and b-tubulin in extracts from islets from 9-month-old mice treated with TGF-b inhibitor or vehicle control. Representative experiment from
n = 3. Error bars indicate 6 SEM. P values were determined by unpaired Student t test. *P < 0.05; **P < 0.01.
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mice (Supplementary Fig. 6A). Despite the increased b-cell
replication upon TGF-b inhibitor treatment of mouse islets
and human islet grafts, and decreased b-cell apoptosis in
mouse islets, the b-cell area, and islet density were not
different between groups (Supplementary Fig. 6B and C).
Thus, treatment with TGF-b inhibitor can be effectively
used to promote replication of human b-cells.
In parallel, we evaluated endogenous islets of the NSG
mice that received the TGF-b inhibitor. Consistent with
our previous data in independent studies (Fig. 4B), the
group that received TGF-b inhibitors exhibited a significant
increase in three different proliferation markers, namely,
BrdU (0.27% 6 0.06 vs. 0.06% 6 0.02, P = 0.028), Ki67
(0.2% 6 0.03 vs. 0.09% 6 0.01, P = 0.047), and pHH3
(0.12% 6 0.02 vs. 0.03% 6 0.02, P = 0.039) (Fig. 6A–C)
in the pancreatic b-cells. Similar to human islet grafts with-
out treatment, b-cell replication in untreated and sham-
operated mice was minimal. In addition, the pancreatic
b-cell proliferation was accompanied by a reduction in
p16INK4a levels in the islets (Fig. 6D). Taken together, our
studies suggest that TGF-b signaling induces age-related
accumulation of p16INK4a, leading to replicative decline
and that treatment with TGF-b inhibitor can effectively
induce replication in both mouse and human b-cells.
DISCUSSION
Previous work on TGF-b signaling has largely focused on
pancreatic development and islet homeostasis and func-
tion (29–34). Here, we delineate the mechanism by which
TGF-b signaling controls replicative senescence across cell
types, including mouse and human b-cells, by regulating
the Ink4a/Arf locus. More importantly, we have used small
molecule inhibitors of the TGF-b pathway to stimulate
mouse and human b-cell replication in vitro and in vivo.
TGF-b signaling is known to inhibit cell proliferation, and
disruptions in TGF-b signaling are associated with over-
coming senescence (35–37), as reviewed by Padua and
Massagué (38). It is important to note that we observed a
two- to threefold increase in b-cell replication with TGF-b
inhibitors, which is comparable to the rates of replication
observed during physiological b-cell mass expansion.
TGF-b1, -2, and -3 ligands are endogenously expressed
within the human pancreas, not just in islets, but also in
ducts as well as in the acini (3). This suggests that TGF-b
ligands may work in both autocrine and paracrine fashion
in the pancreas. TGF-b1 levels have been reported to in-
crease with age in circulation as well as within several
tissues (27,28). TGF-b signaling has been shown to be a
critical signal in pancreatic development (39). Loss of
Figure 4—Immunohistochemistry (A) and quantification (B) for proliferation of b-cells in pancreatic sections from 9-month-old mice injected
intraperitoneally with TGF-b inhibitor or vehicle control, using immunostaining with Ki67 antibody (red) and insulin (green), along with
nuclear counterstain DAPI (blue). Arrows mark the proliferating b-cells, labeled by Ki67 and insulin (n = 9). C: Immunohistochemistry for
p16INK4a levels in pancreatic sections from 9-month-old mice injected intraperitoneally with TGF-b inhibitor or vehicle control, using
immunostaining with p16INK4a antibody (red) and insulin (green), along with DAPI (blue). Representative experiment from n = 9. D: Immu-
nohistochemistry for Ki67 (red), along with insulin (green) and DAPI (blue) for proliferation of b-cells in human islets treated with TGF-b
inhibitor or vehicle control. Arrowheads mark proliferating b-cells. Representative experiment from n = 3. Error bars indicate 6 SEM.
P values were determined by unpaired Student t test. *P < 0.05.
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Figure 5—A–F: Confocal microscopy view of kidney sections derived from human islets (HI) transplanted (Tx) under the kidney capsule and
treated with TGF-b inhibitor. Magnified area highlighted from A (right white box) shows imaging of insulin (red) (B, D and F ), BrdU antibody
(green) (C, D, and F ), and DAPI (blue) (E and F ). Arrows mark proliferating b-cells. Images (original magnification 360) show each
immunofluorescent staining separately (indicating nuclear gap for replicating b-cell surrounded by insulin) for the proliferating b-cells.
Original magnification 325 and 360. Representative experiment from n = 4. Quantification of proliferating b-cells for BrdU/insulin (G),
Ki67/insulin (H), and pHH3/insulin double-positive cells (I) from human islet–grafted and TGF-b inhibitor–treated groups. Between 1,000 and
2,000 b-cells were counted in each section (n = 4). J: Immunohistochemistry for p16INK4a in human islet–grafted kidney sections treated
with or without TGF-b inhibitor, using insulin (red), p16 (green), and DAPI (blue). Representative experiment from n = 4. Error bars indicate 6
SEM. P values were determined by unpaired Student t test. *P < 0.05; **P < 0.01.
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TGF-b type II receptor shows an increase in endocrine
precursors and proliferating endocrine cells, suggesting
that TGF-b signaling modulates the growth and differen-
tiation of endocrine progenitors (40).
Disruptions in the canonical TGF-b signaling in the
exocrine tissue result in islet hypertrophy (31), thus
suggesting a role for TGF-b in regulating b-cell prolifer-
ation and islet homeostasis. Transient loss of Smad7 in
the islets, using an inducible loss of function model,
resulted in islet enlargement (32). More recently, genetic
loss of Smad2 and -3 has been reported to result in a
more robust proliferative response upon b-cell loss (29).
Another study showed loss of Smad2 induced islet hy-
perplasia and impaired insulin secretion (30). Studies
using combined pan-pancreatic knockdown of TGF-b re-
ceptors I and II have also implicated TGF-b signaling in
the regulation of b-cell proliferation (33). However,
most of such work examining the TGF-b signaling on
b-cell proliferation has been performed in the context of
adaptive expansion in permissive age windows. Our work
is the first to identify a key role for TGF-b signaling in
age-dependent proliferative decline in pancreatic b-cells
and to also establish a mechanism of cell cycle control via
the INK4a locus.
Figure 6—A–C: Immunohistochemistry and quantification for proliferating b-cells in pancreatic sections of human islet graft–bearing mice.
Immunoflourescent staining for proliferation markers BrdU (A), Ki67 (B ), and pHH3 (C). All proliferation markers are shown in green, insulin
in red, and nuclear staining in blue. Arrows mark proliferating b-cells. Representative experiment from n = 4. D: Immunohistochemistry for
p16INK4a in pancreatic section from human islet–grafted recipients, treated with or without TGF-b inhibitor, using insulin (red), p16 (green),
and DAPI (blue). Representative experiment from n = 4. Error bars indicate 6 SEM. P values were determined by unpaired Student t test.
HI, human islet; Tx, transplants. *P < 0.05.
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TGF-b has been reported to stimulate insulin secretion
(41), insulin gene transcription, and islet function (34).
Further, TGF-b has been recently reported to have a pro-
tective effect on islet grafts in the murine models (40).
Also, another recent study shows that inhibition of TGF-b
signaling can reverse b-cell dedifferentiation in diabetes,
suggesting an effect on function (42). These studies raise
the possibility that treatment with TGF-b inhibitor may
promote islet function and islet graft survival. In our studies
using human islet grafts in humanized mice, however, the
control and inhibitor-treated mice both showed comparable
graft survival and human insulin and C-peptide secretion
profiles. Considering Ink4a repression by polycomb group
proteins is a well-conserved mechanism across cell types,
additional work that addresses targeting of the small mole-
cule inhibitors of the TGF-b signaling to the islet b-cells is
warranted. Our study for the first time shows the connec-
tion between TGF-b signaling and p16Ink4a-dependent rep-
licative senescence in b-cells, thus providing a mechanistic
insight into the age-dependent decline of b-cell replica-
tion. The experiments presented here establish a novel
link between TGF-b signaling and the epigenetic regula-
tion of b-cell replicative potential. These data provide an
example of a pharmacological agent that can promote the
replication of human b-cells with translational therapeu-
tic potential to restore functional b-cell mass in patients
with diabetes.
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